Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lyzodol
- Development stage
- Unknown
- Lead developer
- MB PHARMA
- Modality
- Whole Cell Cancer Vaccines → Cancer Vaccines → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Split/Subunit Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Oral
01
Overview
Lyzodol is a food supplement developed by MB Pharma, formulated as quick-dissolving oral tablets with a light menthol flavor. It contains inactivated bacterial lysates from four bacterial strains commonly associated with upper respiratory tract infections: *Staphylococcus aureus*, *Klebsiella pneumoniae*, *Lelliottia amnigena*, and *Cutibacterium acnes*. Lyzodol is designed to support the immune response and help prevent or manage respiratory tract inflammation. It is marketed in the Czech Republic and distributed through partners such as TreeMed and Fagofarma.
- Brand names
- Lyzodol
Beyond the preview
Go deeper on Lyzodol.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lyzodol.